Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

15th International Workshop on Chronic Lymphocytic Leukaemia (iwCLL 2013) /
Making sense of the expanding armoury of treatment options for the less fit CLL patient

9th - 11th Sep 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.11.13
Views: 3163

Dr Valentin Goede - Uniklinik Köln, Cologne, Germany

How do we treat the older/unfit CLL patient and which treatment do we chose?

These questions are addressed in this symposium with a review of the data.

An overview is given of chemotherapy treatments, eg, fludarabine, bendamustine, in older/unfit patients.

Dr Goede refers to the phase III data comparing bendamustine with chlorambucil with benefits observed on PFS with bendamustine.

Addressing whether chemoimmunotherapy, eg, chlorambucil-based and bendamustine-based chemoimmunotherapy, can be used in older/unfit patients, data are presented suggesting the promise observed to date. Dr Goede goes on to outline the on-going MaBLe study comparing bendamustine plus rituximab with chlorambucil plus rituximab, with preliminary results showing a higher complete response after six treatment cycles with the bendamustine vs. chlorambucil combination, with similar adverse events.

In terms of new drugs, Dr Goede reviews promising data so far for lenalidomide, TKIs, eg, ibrutinib, and the novel CD20 antibodies in older/unfit patients.  So, how should clinicians use the various treatments in the older/unfit patient?  Dr Goede shares his views on this important question.


Content taken from a Mundipharma sponsored satellite symposium at iwCLL 2013 as part of the official programme.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation